When multiple myeloma relapses

RESPOND with the power of Kyprolis®-based regimen (Kd)

Kd progression-free survival

ENDEAVOR The primary endpoint of the trial was PFS, with the results being 18.7 months median PFS with Kd vs 9.4 months with Vd.1 A Kd regimen resulted in a significant increase in PFS vs a Vd regimen – giving patients more time without disease progression.1

Adapted from Dimopoulos et al.1

Kyprolis® has a tolerable safety profile in combination with dexamethasone Detailed treatment regimen in the Kd head-to-head phase 3 ENDEAVOR study

Consistently superior median PFS with or without prior bortezomib1

In a pre-planned exploratory subgroup analysis, patients with or without prior exposure to bortezomib had superior median PFS with Kd vs Vd.1

Adapted from Dimopoulos et al.1

Increase your relapsed multiple myeloma patients’ time without progression of the disease independent of prior treatment

Please read the SmPC for full comprehensive safety information

References

  1. Dimopoulos MA et al. Lancet Oncol 2016;17:27–38.

Terms of Use

The information contained in this site is for European healthcare professionals only.

Kyprolis